Solana Company Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, and governance procedures. All proposals passed, with new and returning directors elected and the auditor confirmed. No shareholder questions were raised during the session.
-
Q1 2026 saw exponential revenue growth driven by staking, despite a 32% SOL price drop leading to large unrealized losses. Strategic capital raises, share repurchases, and divestitures position the company for recurring revenue growth in APAC digital assets.
Fiscal Year 2025
-
Q4 2025 saw strong staking yields, a $325.6M net income driven by derivative gains, and a 14% increase in SOL per share. Strategic initiatives included the Pacific Backbone and a tri-party custody model, positioning the company for further growth in the Solana ecosystem.
-
Raised over $500 million to fund a digital asset treasury strategy, with Pantera and Summer Capital as major backers. Reported a net loss of $352.8 million due to large non-operating charges, but achieved strong staking yields and expanded SOL holdings.
Fiscal Year 2024
-
Management is contesting CMS's reimbursement rates for PoNS devices, seeking higher pricing based on market comparables and warning that delays are hindering commercialization and financial stability. Strategic alternatives are being explored to maximize value, while pivotal stroke study enrollment remains on track.
-
Q2 2024 revenue declined year-over-year but rose 35% sequentially, with major reimbursement milestones achieved, including VA, DOD, and third-party insurer contracts. Medicare reimbursement is expected to drive significant revenue growth from October, and stroke FDA submission remains on track for 2025.